CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Titel:
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Auteur:
O'Hara, Mark H O'Reilly, Eileen M Varadhachary, Gauri Wolff, Robert A Wainberg, Zev A Ko, Andrew H Fisher, George Rahma, Osama Lyman, Jaclyn P Cabanski, Christopher R Mick, Rosemarie Gherardini, Pier Federico Kitch, Lacey J Xu, Jingying Samuel, Theresa Karakunnel, Joyson Fairchild, Justin Bucktrout, Samantha LaVallee, Theresa M Selinsky, Cheryl Till, Jacob E Carpenter, Erica L Alanio, Cécile Byrne, Katelyn T Chen, Richard O Trifan, Ovid C Dugan, Ute Horak, Christine Hubbard-Lucey, Vanessa M Wherry, E John Ibrahim, Ramy Vonderheide, Robert H